Search results
Order by most recent / most popular / relevance
Results: 1-10 of 165
Prohibition not granted as non-infringement allegation held justified
- Borden Ladner Gervais LLP
- -
- Canada
- -
- July 18 2012
The Court heard this application and the next application consecutively and issued decisions on the same day, however, indicated that each was considered separately
Intellectual property weekly abstracts bulletin
- Borden Ladner Gervais LLP
- -
- Canada, USA
- -
- May 22 2013
The Supreme Court has dismissed Eli Lilly of Canada Inc.’s leave on the issue, as summarized by the Court, as to whether the creation by the Federal
Teva Canada Innovation v. Attorney General of Canada
- Borden Ladner Gervais LLP
- -
- Canada
- -
- May 8 2013
The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an
Compound patent found valid in face of allegations of lack of utilitysound prediction and insufficiency
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 27 2013
Apotex and Novopharm started actions to impeach Novartis’ patent covering the compound imatinib, sold under the brand name GLEEVEC. They then sent
Patent application rejected again for obviousness
- Borden Ladner Gervais LLP
- -
- Canada
- -
- May 28 2012
The Commissioner had previously refused the patent application on the basis of obviousness
Only authorized correspondent can pay maintenance fees for application
- Borden Ladner Gervais LLP
- -
- Canada
- -
- November 14 2011
The Judge found that the acceptance of maintenance fees paid within the grace period by someone other than the authorized correspondent reinstated a lapsed patent application, but the subsequent reimbursement of those fees nullified the reinstatement
Court grants motion to reopen trial and admit new evidence
- Borden Ladner Gervais LLP
- -
- Canada
- -
- April 27 2011
The Federal Court granted leave to reopen the trial and admit new evidence in a matter under reserve, in which no reasons or judgement have issued
NOC proceeding dismissed on the basis of overbreadth and a lack of sound prediction
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 13 2013
In this case, one claim of a patent was at issue in the proceeding. The claim related to the use of pregabalin or its racemate to treat pain. The
Pfizer Canada v. Genpharm ULC and Mylan Pharmaceuticals et al
- Borden Ladner Gervais LLP
- -
- Canada
- -
- July 5 2010
This is a motion brought in the context of a proceeding under the Patented Medicines (Notice of Compliance) Regulations (Regulations) pursuant to Section 6(5)(b) of the Regulations
Question remitted to the court a second time for redetermination
- Borden Ladner Gervais LLP
- -
- Canada
- -
- October 25 2012
The Court of Appeal remitted a case to the Court, requiring the Court to redetermine whether Corlac had infringed a method claim by inducement
Current Search
- Workarea - Patents
- Workarea - Litigation
- Author - Chantal Saunders
Suggested Facets
Author
- Adrian Howard (8)
- Anne Kinsman (1)
- Beverley Moore (164)
- Mukundan Chakrapani, Ph.D (1)
- Steven Kennedy (1)